Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project

被引:15
|
作者
de Wilde, Arno [1 ]
Ossenkoppele, Rik [1 ,2 ,3 ]
Pelkmans, Wiesje [1 ]
Bouwman, Femke [1 ]
Groot, Colin [1 ,2 ]
van Maurik, Ingrid [1 ]
Zwan, Marissa [1 ]
Yaqub, Maqsood [2 ]
Barkhof, Frederik [2 ,4 ,5 ]
Lammertsma, Adriaan A. [2 ]
Biessels, Geert Jan [6 ]
Scheltens, Philip [1 ]
van Berckel, Bart N. [1 ,2 ]
van der Flier, Wiesje M. [1 ,7 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam UMC, Alzheimer Ctr, Dept Neurol,Amsterdam Neurosci, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Neurosci, Dept Radiol & Nucl Med, Amsterdam, Netherlands
[3] Lund Univ, Clin Memory Res Unit, Malmo, Sweden
[4] UCL, Inst Neurol, London, England
[5] UCL, Inst Healthcare Engn, London, England
[6] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands
[7] Vrije Univ Amsterdam, Amsterdam Neurosci, Dept Epidemiol & Biostat, Amsterdam, Netherlands
关键词
Alzheimer's disease; Amyloid; Positron emission tomography; Appropriate use criteria; Dementia; Clinical practice; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS ASSOCIATION WORKGROUPS; NATIONAL INSTITUTE; DIAGNOSTIC GUIDELINES; TASK-FORCE; DISEASE; RECOMMENDATIONS; BIOMARKERS; DEMENTIA; MANAGEMENT;
D O I
10.1016/j.jalz.2019.07.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post-positron emission tomography diagnosis and management change between "AUC-consistent" and "AUC-inconsistent" patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post-positron emission tomography diagnosis (28%-21%) and management (32%-17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not. (C) 2019 The Authors. Published by Elsevier Inc.
引用
收藏
页码:1458 / 1467
页数:10
相关论文
共 50 条
  • [41] Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay
    Dyer, Adam H.
    Dolphin, Helena
    O'Connor, Antoinette
    Morrison, Laura
    Sedgwick, Gavin
    Young, Conor
    Killeen, Emily
    Gallagher, Conal
    Mcfeely, Aoife
    Connolly, Eimear
    Davey, Naomi
    Claffey, Paul
    Doyle, Paddy
    Lyons, Shane
    Gaffney, Christine
    Ennis, Ruth
    Mchale, Cathy
    Joseph, Jasmine
    Knight, Graham
    Kelly, Emmet
    O'Farrelly, Cliona
    Fallon, Aoife
    O'Dowd, Sean
    Bourke, Nollaig M.
    Kennelly, Sean P.
    ALZHEIMERS RESEARCH & THERAPY, 2024, 16 (01)
  • [42] Appropriate Use Criteria for PET Myocardial Perfusion Imaging
    Schindler, Thomas H.
    Bateman, Timothy M.
    Berman, Daniel S.
    Chareonthaitawee, Panithaya
    De Blanche, Lorraine E.
    Dilsizian, Vasken
    Dorbala, Sharmila
    Gropler, Robert J.
    Shaw, Leslee
    Soman, Prem
    Winchester, David E.
    Verberne, Hein
    Ahuja, Sukhjeet
    Beanlands, Rob S.
    Di Carli, Marcelo F.
    Murthy, Venkatesh L.
    Ruddy, Terrence D.
    Schwartz, Ronald G.
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (08) : 1221 - 1265
  • [43] Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine
    Booij, Jan
    Arbizu, Javier
    Darcourt, Jacques
    Hesse, Swen
    Nobili, Flavio
    Payoux, Pierre
    Pappata, Sabina
    Tatsch, Klaus
    Walker, Zuzana
    Pagani, Marco
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (07) : 1122 - 1125
  • [44] Frailty, MRI, and FDG-PET Measures in an Australian Memory Clinic Cohort
    Jordan, Nan
    Gvalda, Matthew
    Cody, Ross
    Galante, Olivia
    Haywood, Cilla
    Yates, Paul
    FRONTIERS IN MEDICINE, 2021, 7
  • [45] Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context
    Nobili, Flavio
    Cagnin, Annachiara
    Calcagni, Maria L.
    Chincarini, Andrea
    Guerra, Ugo P.
    Morbelli, Silvia
    Padovani, Alessandro
    Paghera, Barbara
    Pappata, Sabina
    Parnetti, Lucilla
    Sestini, Stelvio
    Schillaci, Orazio
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (01) : 83 - 92
  • [46] Cerebral Amyloid Angiopathy in Amyloid-Positive Patients from a Memory Clinic Cohort
    Costa, Ana Sofia
    Pinho, Joao
    Kucikiene, Domante
    Reich, Arno
    Schulz, Joerg B.
    Reetz, Kathrin
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 79 (04) : 1661 - 1672
  • [47] A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [18F]flortaucipir PET in a memory clinic cohort
    Gregory Mathoux
    Cecilia Boccalini
    Debora E. Peretti
    Annachiara Arnone
    Federica Ribaldi
    Max Scheffler
    Giovanni B. Frisoni
    Valentina Garibotto
    European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51 : 1639 - 1650
  • [48] Incremental diagnostic value of 18F-Fluetemetamol PET in differential diagnoses of Alzheimer's Disease-related neurodegenerative diseases from an unselected memory clinic cohort
    Bao, Yi-Wen
    Shea, Yat-Fung
    Chiu, Patrick Ka-Chun
    Kwan, Joseph S. K.
    Chan, Felix Hon-Wai
    Mak, Henry Ka-Fung
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [49] Defining a Centiloid Scale threshold predicting long-term progression to dementia in patients attending the Memory Clinic: An [18F]-Flutemetamol amyloid-PET study
    Hanseeuw, B.
    Lhommel, R.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2020, 44 (02): : 138 - 139
  • [50] Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort
    Hirtz, Christophe
    Busto, Germain U.
    Bennys, Karim
    Kindermans, Jana
    Navucet, Sophie
    Tiers, Laurent
    Lista, Simone
    Vialaret, Jerome
    Gutierrez, Laure-Anne
    Dauvilliers, Yves
    Berr, Claudine
    Lehmann, Sylvain
    Gabelle, Audrey
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)